Status | Study |
Completed |
Study Name: A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I Condition: Cognitive Decline Mucopolysaccharidosis I Date: 2009-02-25 Interventions: Drug: laronidase For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazym |
Terminated |
Study Name: Clinical Trial of Growth Hormone in MPS I, II, and VI Condition: Mucopolysaccharidosis I Mucopolysaccharidosis II Date: 2008-09-08 Interventions: Drug: Somatropin (DNA origin) The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divid |
Completed |
Study Name: Immune Tolerance Study With Aldurazyme® (Laronidase) Condition: Mucopolysaccharidosis I Date: 2008-08-13 Interventions: Biological: Laronidase 0.058 m |
Terminated |
Study Name: Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I Condition: Spinal Cord Compression Mucopolysaccharidosis I Date: 2008-06-17 Interventions: Drug: laronidase 1.74 mg intrathecally every 1-3 months for 1 year |
Active, not recruiting |
Study Name: Intrathecal Enzyme Replacement for Hurler Syndrome Condition: Hurler Syndrome Date: 2008-03-11 Interventions: Drug: IRT Laronidase Laronidase belongs to a class of drug |
Recruiting |
Study Name: A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants Condition: Mucopolysaccharidosis I Hurler's Syndrome Date: 2007-01-03 Interventions: Biological: Aldurazyme (laronidase) dose of 0.58mg/kg body weight intravenously (IV) every week |
Completed |
Study Name: Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease Condition: Mucopolysaccharidosis I Hurler Syndrome Date: 2005-11-22 Interventions: Biological: Aldurazyme (Recombinant Human Alpha-L-Iduronidase) 0.58 mg/kg every week |
Terminated |
Study Name: Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I Condition: Mucopolysaccharidosis I Lysosomal Storage Diseases Date: 2005-09-19 Interventions: Drug: laronidase 0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per mont |
Completed |
Study Name: Stem Cell Transplant w/Laronidase for Hurler Condition: Mucopolysaccharidosis I Hurler Syndrome Date: 2005-09-12 Interventions: Procedure: Stem Cell Transplant |
Recruiting |
Study Name: Mucopolysaccharidosis I (MPS I) Registry Condition: Mucopolysaccharidosis I (MPS I) Date: 2005-09-02 |